After big 2016 setback, field of microbiome-based drugs gets injection of promise with positive signal from Rebiotix pivotal study
Several years ago, as companies capitalizing on science that suggests flushing ‘good’ gut bacteria into the system can treat a plethora of conditions — from C. diff infections to obesity — began to gain traction, the opportunities to harness the microbiome garnered feverish promise and generous funding. Then, in 2016, Seres Therapeutics’ failure in a mid-stage trial evaluating its “crapsule” — donor-derived processed fecal material encapsulated in a pill — derailed the emerging field, relegating the microbiome from hero to zero status.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.